| Literature DB >> 31628740 |
Dabor Resiere1, Hossein Mehdaoui1, Rémi Névière2, Claude Olive3, Mathieu Severyns4, Adeline Beaudoin4, Jonathan Florentin1, Yannick Brouste1, Rishika Banydeen1, André Cabié5, Bruno Mégarbane6, José María Gutiérrez7, Hatem Kallel8.
Abstract
Infections secondary to snakebite occur in a number of patients and are potentially life-threatening. Bothrops lanceolatus bites in Martinique average 30 cases per year and may result in severe thrombotic and infectious complications. We aimed to investigate the infectious complications related to B. lanceolatus bite. A retrospective single-center observational study over 7 years (2011-2018) was carried out, including all patients admitted to the hospital because of B. lanceolatus bite. One hundred seventy snake-bitten patients (121 males and 49 females) were included. Thirty-nine patients (23%) presented grade 3 or 4 envenoming. Twenty patients (12%) developed wound infections. The isolated bacteria were Aeromonas hydrophila (3 cases), Morganella morganii (two cases), group A Streptococcus, and group B Streptococcus (one case each). Patients were treated empirically with third-generation cephalosporin (or amoxicillin-clavulanate), aminoglycoside, and metronidazole combinations. Outcome was favorable in all patients. The main factor significantly associated with the occurrence of infection following snakebite was the severity of envenoming (P < 0.05). Our findings clearly point toward the frequent onset of infectious complications in B. lanceolatus-bitten patients presenting with grade 3 and 4 envenoming. Thus, based on the bacteria identified in the wounds, we suggest that empiric antibiotic therapy including third-generation cephalosporin should be administered to those patients on hospital admission.Entities:
Mesh:
Substances:
Year: 2020 PMID: 31628740 PMCID: PMC6947800 DOI: 10.4269/ajtmh.19-0369
Source DB: PubMed Journal: Am J Trop Med Hyg ISSN: 0002-9637 Impact factor: 2.345
Severity score of envenoming after Bothrops lanceolatus bite (adapted from ref. 11)
| Grade | Severity | Symptoms |
|---|---|---|
| 1 | Minor | No swelling |
| No pain | ||
| No general signs | ||
| 2 | Moderate | Local swelling confined to two segments of the bitten limb |
| Moderate pain | ||
| No general signs | ||
| 3 | Severe | Regional edema, extension of swelling beyond two segments of the bitten limb |
| Persistent and resistant pain to analgesics | ||
| No general signs | ||
| 4 | Major | Swelling spreading to the trunk |
| General signs (vomiting, headache, and abdominal or chest pain) | ||
| Hypotension | ||
| Isolated thrombocytopenia | ||
| Disseminated intravascular coagulation |
Severity is defined by at least one confirmed item.
Clinical parameters recorded in 170 Bothrops lanceolatus–bitten patients on hospital admission
| Variables | Total patients ( | Infected patients ( | Noninfected patients ( | |
|---|---|---|---|---|
| Age (years) | 45 ± 18 | 48 ± 15 | 45 ± 18 | 0.4 |
| Male, | 121 (71%) | 15 (75%) | 106 (71%) | 0.7 |
| Hospitalization, | 107 (63%) | 20 (100%) | 87 (58%) | < 0.0001 |
| Past medical history | ||||
| Snakebite, | 10 (6%) | 1 (5%) | 9 (6%) | 0.9 |
| Immunosuppression, | 4 (2%) | 2 (10%) | 2 (1%) | 0.02 |
| Cardiovascular risk, | 28 (17%) | 3 (15%) | 25 (17%) | 0.9 |
| Coagulopathy, | 4 (2%) | 2 (10%) | 2 (1%) | 0.02 |
| Snakebite characteristics | ||||
| Time from envenoming to admission (hours) | 3.5 ± 4.3 | 3.7 ± 4.7 | 3.5 ± 4.3 | 0.8 |
| Snake captured, | 45 (27%) | 8 (40%) | 37 (25%) | 0.1 |
| Site of the bite, | 0.8 | |||
| Upper limb | 71 (42%) | 10 (50%) | 61 (41%) | |
| Lower limb | 98 (58%) | 10 (50%) | 88 (59%) | |
| Buttock | 1 (1%) | 0 | 1 (1%) | |
| Local bleeding, | 91 (54%) | 11 (55%) | 80 (53%) | 0.9 |
| Local pain, | 163 (96%) | 19 (95%) | 144 (96%) | 0.833 |
| Envenoming grade, | ||||
| 1 | 22 (13%) | 0 | 22 (15%) | – |
| 2 | 109 (64%) | 8 (40%) | 101 (67%) | – |
| 3 | 33 (19%) | 8 (40%) | 25 (17%) | – |
| 4 | 6 (4%) | 4 (20%) | 2 (1%) | – |
| Clinical presentation and complications | ||||
| Heart rate (beat/min) | 80 ± 16 | 79 ± 16 | 80 ± 16 | 0.9 |
| Temperature (°C) | 36.8 ± 0.8 | 37.1 ± 0.7 | 36.8 ± 0.5 | 0.7 |
| Systolic arterial pressure (mmHg) | 137 ± 24 | 128 ± 27 | 139 ± 23 | 0.04 |
| Diastolic arterial pressure (mmHg) | 80 ± 15 | 75 ± 14 | 81 ± 15 | 0.1 |
| Mean arterial pressure (mmHg) | 99 ± 16 | 93 ± 17 | 100 ± 16 | 0.05 |
| SpO2 (%) | 99 ± 2 | 99 ± 1 | 98 ± 2 | 0.07 |
| Shock, | 3 (1.8%) | 3 (15%) | 0 | – |
| Consciousness impairment, | 3 (1.8%) | 3 (15%) | 0 | – |
| Convulsion, | 1 (0.6%) | 1 (5%) | 0 | – |
| Thrombosis, | 1 (1%) | 0 | 1 (1%) | – |
| Compartmental syndrome, | 6 (4%) | 5 (25%) | 1 (1%) | – |
| Bacteremia, | 3 (2%) | 3 (15%) | 0 | – |
| Laboratory parameters on admission | ||||
| Creatine kinase (IU/L) | 300 ± 283 | 311 ± 257 | 298 ± 287 | 0.9 |
| Platelet count (G/L) | 238 ± 67 | 213 ± 76 | 241 ± 65 | 0.07 |
| Prothrombin index (%) | 96 ± 13 | 92 ± 17 | 97 ± 12 | 0.09 |
| Activated partial thromboplastin time (minutes) | 31.5 ± 3.7 | 30.6 ± 3.6 | 31.6 ± 3.7 | 0.3 |
| Fibrinogen (g/L) | 3.0 ± 0.7 | 2.9 ± 1.0 | 3.0 ± 0.6 | 0.7 |
| C-reactive protein (mg/L) | 7 ± 42 | 31 ± 118 | 4 ± 7 | 0.009 |
| White blood cells (G/L) | 7.8 ± 2.7 | 9.3 ± 3.6 | 7.6 ± 2.4 | 0.005 |
| Antivenom management | ||||
| Antivenom administration, | 154 (91%) | 19 (95%) | 135 (90%) | 0.5 |
| Number of vials | 1.7 ± 1.3 | 2.4 ± 1.5 | 1.6 ± 1.3 | 0.016 |
| Time from snakebite to antivenom administration (hour) | 6.0 ± 7.0 | 6.5 ± 8.9 | 5.9 ± 6.8 | 0.8 |
| Time from admission to antivenom administration (hour) | 3.2 ± 5.3 | 4.3 ± 7.5 | 3.1 ± 5.0 | 0.4 |
| Antivenom reinjection, | 19 (12%) | 10 (53%) | 9 (7%) | < 0.001 |
| Empiric antibiotic administration, | 37 (22%) | 17 (85%) | 20 (13%) | – |
| Amoxicillin–clavulanate, | 11 (6%) | 2 (10%) | 9 (6%) | – |
| Third-generation cephalosporin, | 17 (10%) | 6 (30%) | 11 (7%) | – |
| Gentamycin, | 12 (7%) | 4 (20%) | 8 (5%) | – |
| Metronidazole, | 12 (7%) | 5 (25%) | 7 (5%) | – |
Figure 1.Distribution of the 170 Bothrops lanceolatus bite cases according to the year (A) and month (B and C) of the study.
Figure 2.Relationship between the monthly distribution of Bothrops snakebites and the recorded rainfall (A) and maximal temperatures (B and C). The line shows the trend in snakebites when the recorded maximal temperature is above 30°C. Stars represent cases with Aeromonas hydrophila infection and circles represent cases with Morganella morganii infection. This figure appears in color at
Figure 3.Prevalence of infection according to the grade of envenoming. This figure appears in color at
Local signs recorded in 170 infected and noninfected Bothrops lanceolatus–bitten patients
| Total patients ( | Infected patients ( | Noninfected patients ( | |
|---|---|---|---|
| Increasing pain | 28 (17%) | 20 (100%) | 8 (5%) |
| Abscess | 7 (4%) | 7 (35%) | 0 |
| Erythema | 17 (10%) | 16 (80%) | 1 (1%) |
| Cellulitis | 4 (2%) | 4 (20%) | 0 |
| Necrosis | 5 (3%) | 5 (25%) | 0 |
| Necrotic fasciitis | 1 (1%) | 1 (5%) | 0 |
| Gangrene | 0 | 0 | 0 |
Figure 4.Length of hospital stay according to the grade of envenoming in 170 Bothrops lanceolatus–bitten patients.
Bacteriological characteristics of wound infection following snakebite described in the literature
| Reference | Chen et al. | Mao et al. | Hsieh et al. | Wagener et al. | Garg et al. | Sachett et al. | Jorge et al. | Our study |
|---|---|---|---|---|---|---|---|---|
| Year of publication | 2011 | 2016 | 2017 | 2017 | 2009 | 2017 | 1994 | 2019 |
| Geographic region | Taiwan | Taiwan | Taiwan | South Africa | India | Brazil | Brazil | Martinique |
| Responsible snake | – | |||||||
| Number of bitten patients, | 231 | 112 | 148 | 164 | – | 187 | – | 170 |
| Number of infected patients, | 21 (9%) | 86 (77%) | 42 (28%) | 42 (26%) | 43 | 74 (40%) | 40 | 20 (12%) |
| Number of positive samples, | 21 (100%) | 50 (58%) | 21 (50%) | 40 (95%) | 43 | 6 (8.1%) | 40 | 7 (35%) |
| Number of isolated strains, | 61 | 113 | 49 | 66 | 53 | 7 | 54 | 7 |
| Aerobic Gram-positive bacteria, | 14 (23%) | 28 (24.8%) | 13 (27%) | 31 (47%) | 28 (53%) | 1 (14%) | 11 (20%) | 2 (10%) |
| 12 | 21 | 11 | 31 | 4 | ||||
| Coagulase-negative | 1 | 4 | – | – | 5 | – | – | – |
| 1 | 1 | – | – | – | – | – | – | |
| – | 2 | 2 | 17 | 1 | ||||
| – | – | – | – | 2 | – | 11 | 2 | |
| Aerobic Gram-negative bacteria, N (%) | 39 (64%) | 77 (68.1%) | 24 (49%) | 35 (53%) | 25 (47%) | 6 (86%) | 37 (69%) | 5 (25%) |
| – | 1 | 2 | – | 2 | – | – | – | |
| – | 7 | 1 | – | – | – | – | 3 | |
| 1 | – | – | – | – | – | – | – | |
| 3 | 2 | – | 1 | – | – | – | – | |
| 2 | 5 | – | 1 | 8 | – | 3 | – | |
| – | – | 3 | 2 | 2 | – | 4 | – | |
| 1 | 1 | 1 | 4 | – | – | – | ||
| 14 | 32 | 12 | 17 | 3 | 6 | 23 | 2 | |
| 5 | 8 | 3 | 10 | 3 | – | – | – | |
| 3 | 6 | – | – | – | – | 7 | – | |
| 5 | 6 | – | – | 3 | – | – | – | |
| – | – | – | 3 | – | – | – | – | |
| 1 | 1 | – | – | – | – | – | – | |
| 1 | 2 | – | – | – | – | – | – | |
| 3 | 5 | – | – | – | – | – | – | |
| – | 1 | – | – | – | – | – | – | |
| Anaerobic bacteria, | 8 (13%) | 7 (6.2%) | 3 (6%) | – | – | – | 6 (11%) | – |
| 6 | 7 | 3 | – | – | – | 6 | – | |
| 2 | – | – | – | – | – | – | – | |
| Fungus, | – | 1 (0.9%) | – | – | – | – | – | – |
| – | 1 | – | – | – | – | – | – | |
| Others, | – | – | 9 (18%) | – | – | – | – | – |
| No growth (% of infected patients), | 0 | 36 (41.9%) | 21 (50%) | 2 (5%) | 0 | 68 (91.9%) | 0 | 13 (65%) |